The FDA has approved the marketing of fenofibric acid (Trilipix – Abbott) to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia on optimal doses of a HMG-CoA reductase inhibitor (statin) who have, or have risk factors for, coronary heart disease. It is the first fibrate approved by the FDA specifically for combined use with a statin. Trilipix is also approved as monotherapy for hypertriglyceridemia, hypercholesterolemia and low HDL-C. The patent for Tricor, Abbott’s older formulation of fenofibrate, will expire in 2011.

FENOFIBRATES — Fenofibrate is available in nonmicronized tablets and capsules that are poorly absorbed and usually must be taken with a meal, and in micronized capsules that are more reliably absorbed. Fenofibric acid is the active metabolite of fenofibrate. Trilipix is the active choline salt of fenofibric acid; it is available as a delayed-release ... more      

Would you like to read the rest of this article?  Gain access below.